BACKGROUND: The mechanisms and relevance of impaired glucose homeostasis in advanced heart failure (HF) are poorly understood. The study goals were to examine glucose regulation, pancreatic endocrine function, and metabolic factors related to prognosis in patients with nondiabetic advanced HF. METHODS AND RESULTS: In total, 140 advanced HF patients without known diabetes mellitus and 21 sex-, age-, and body mass index-matched controls underwent body composition assessment, oral glucose tolerance testing, and measurement of glucose-regulating hormones to model pancreatic β-cell secretory response. Compared with controls, HF patients had similar fasting glucose and insulin levels but higher levels after oral glucose tolerance testing. Insulin secretion was not impaired, but with increasing HF severity, there was a reduction in glucose, insulin, and insulin/glucagon ratio-a signature of starvation. The insulin/C-peptide ratio was decreased in HF, indicating enhanced insulin clearance, and this was correlated with lower cardiac output, hepatic insufficiency, right ventricular dysfunction, and body wasting. After a median of 449 days, 41% of patients experienced an adverse event (death, urgent transplant, or assist device). Increased glucagon and, paradoxically, low fasting plasma glucose displayed the strongest relations to outcome (P=0.01). Patients in the lowest quartile of fasting plasma glucose (3.8-5.1 mmol·L-1, 68-101 mg·dL-1) had 3-times higher event risk than in the top quartile (6.0-7.9 mmol·L-1, 108-142 mg·dL-1; relative risk: 3.05 [95% confidence interval, 1.46-6.77]; P=0.002). CONCLUSIONS: Low fasting plasma glucose and increased glucagon are robust metabolic predictors of adverse events in advanced HF. Pancreatic insulin secretion is preserved in advanced HF, but levels decrease with increasing HF severity due to enhanced insulin clearance that is coupled with right heart failure and cardiac cachexia.

CNR Institute of Neuroscience Padova Italy

Department of Cardiovascular Disease Mayo Clinic Rochester MN

Institute for Clinical and Experimental Medicine IKEM Prague Czech Republic

Zobrazit více v PubMed

Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e535–e578. PubMed

Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334–341. PubMed

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. PubMed

Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol. 2004;44:78–81. PubMed

Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism. 1991;40:972–977. PubMed

Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019–1026. PubMed

Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527–532. PubMed

Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–508. PubMed PMC

Margulies KB. Evolving challenges for targeting metabolic abnormalities in heart failure. JACC Heart Fail. 2016;4:567–569. PubMed

Collins S. A heart‐adipose tissue connection in the regulation of energy metabolism. Nat Rev Endocrinol. 2014;10:157–163. PubMed

Polak J, Kotrc M, Wedellova Z, Jabor A, Malek I, Kautzner J, Kazdova L, Melenovsky V. Lipolytic effects of B‐type natriuretic peptide1‐32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol. 2011;58:1119–1125. PubMed

Melenovsky V, Kotrc M, Borlaug BA, Marek T, Kovar J, Malek I, Kautzner J. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 2013;62:1660–1670. PubMed

Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole‐Wilson PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534. PubMed

Doehner W, Pflaum CD, Rauchhaus M, Godsland IF, Egerer K, Cicoira M, Florea VG, Sharma R, Bolger AP, Coats AJ, Anker SD, Strasburger CJ. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol. 2001;145:727–735. PubMed

Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb‐Peploe KM, Harrington D, Kox WJ, Poole‐Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053. PubMed

Tura A, Pacini G, Kautzky‐Willer A, Gastaldelli A, DeFronzo RA, Ferrannini E, Mari A. Estimation of prehepatic insulin secretion: comparison between standardized c‐peptide and insulin kinetic models. Metabolism. 2012;61:434–443. PubMed

Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta ‐cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283:E1159–E1166. PubMed

Cersosimo E, Solis‐Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic beta‐cell function: review of methods and clinical applications. Curr Diabetes Rev. 2014;10:2–42. PubMed PMC

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. PubMed

Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J, Jarolim P. Association of fibroblast growth factor‐23 levels and angiotensin‐converting enzyme inhibition in chronic systolic heart failure. JACC Heart Fail. 2015;3:829–839. PubMed

AlZadjali MA, Godfrey V, Khan F, Choy A, Doney AS, Wong AK, Petrie JR, Struthers AD, Lang CC. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747–753. PubMed

Swan JW, Walton C, Godsland IF. Assessment of insulin sensitivity in man: a comparison of minimal model‐ and euglycaemic clamp‐derived measures in health and heart failure. Clin Sci (Lond). 1994;86:317–322. PubMed

Melenovsky V, Kotrc M, Polak J, Pelikanova T, Bendlova B, Cahova M, Malek I, Jarolim P, Kazdova L, Kautzner J. Availability of energetic substrates and exercise performance in heart failure with or without diabetes. Eur J Heart Fail. 2012;14:754–763. PubMed

Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19:608–624. PubMed

Bonora E, Zavaroni I, Coscelli C, Butturini U. Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism. 1983;32:438–446. PubMed

Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulkki K, Harkonen M. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996;28:665–672. PubMed

Sharma B, Majid PA, Pakrashi BC, Dykes JR, Taylor SH. Insulin secretion in heart failure. Br Med J. 1970;2:396–398. PubMed PMC

Melenovsky V, Benes J, Skaroupkova P, Sedmera D, Strnad H, Kolar M, Vlcek C, Petrak J, Benes J Jr, Papousek F, Oliyarnyk O, Kazdova L, Cervenka L. Metabolic characterization of volume overload heart failure due to aorto‐caval fistula in rats. Mol Cell Biochem. 2011;354:83–96. PubMed

Hait G, Corpus M, Lamarre FR, Yuan SH, Kypson J, Cheng G. Alteration of glucose and insulin metabolism in congenital heart disease. Circulation. 1972;46:333–346. PubMed

Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808–1817. PubMed PMC

Frayn KN. Metabolic Regulation: A Human Perspective. Oxford: Blackwell Science; 2003.

Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4–12. PubMed PMC

Cahill GF Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, Reichard GA Jr, Kipnis DM. Hormone‐fuel interrelationships during fasting. J Clin Invest. 1966;45:1751–1769. PubMed PMC

Lommi J, Koskinen P, Naveri H, Harkonen M, Kupari M. Heart failure ketosis. J Intern Med. 1997;242:231–238. PubMed

Wandell PE, Theobald H. The association between low fasting blood glucose value and mortality. Curr Diabetes Rev. 2007;3:274–279. PubMed

Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all‐cause mortality. Circulation. 2000;101:2047–2052. PubMed

Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail‐Beigi F, Grimm RH Jr, Probstfield JL, Simons‐Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. PubMed PMC

Benzing G III, Schubert W, Sug G, Kaplan S. Simultaneous hypoglycemia and acute congestive heart failure. Circulation. 1969;40:209–216. PubMed

Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, Hernandez AF. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol. 2013;61:2397–2405. PubMed

Block MB, Gambetta M, Resnekov L, Rubenstein AH. Spontaneous hypoglycaemia in congestive heart‐failure. Lancet. 1972;2:736–738. PubMed

Mellinkoff SM, Tumulty PA. Hepatic hypoglycemia; its occurrence in congestive heart failure. N Engl J Med. 1952;247:745–750. PubMed

Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE, Schmitz O, Jorgensen JO, Christiansen JS, Moller N. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med. 2006;260:11–21. PubMed

Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes. 1971;20:834–838. PubMed

Bedi KC Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133:706–716. PubMed PMC

Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642. PubMed

Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452–3462. PubMed PMC

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial